The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - A prospective study

Vaccine

Volumn 32, Issue 44, 2014, Pages 5787-5793

  Abu Raya, Bahaa ^a,b   Srugo, Isaac ^a,b   Kessel, Aharon ^a,b   Peterman, Michael ^a,b   Bader, David ^a,b   Gonen, Ron ^a,b   Bamberger, Ellen ^a,b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Immunoglobulin G transfer; Maternal immunization; Pertussis; Tetanus diphtheria acellular pertussis

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTUSSIS ANTIBODY; PERTUSSIS TOXIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNIZATION; INTERNATIONAL STANDARD UNIT; NEWBORN; NORMAL HUMAN; PREGNANCY; PREGNANT WOMAN; PROSPECTIVE STUDY; TREATMENT DURATION; UMBILICAL CORD BLOOD; BLOOD; FETUS BLOOD; IMMUNOLOGY; MALE; MIDDLE AGED; PASSIVE IMMUNIZATION; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

ADULT; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; FETAL BLOOD; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT, NEWBORN; MALE; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

EID: 84908065071     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.038     Document Type: Article

References (42)

1. Cherry J.D. Epidemic pertussis in 2012 - the resurgence of a vaccine preventable disease. N Engl J Med 2012, 367:785-787.
2. Centers for Disease Control Prevention (CDC) Pertussis epidemic - Washington, 2012. MMWR Morb Mortal Wkly Rep 2012, 61:517-522.
3. Winter K., Harriman K., Zipprich J., et al. California pertussis epidemic, 2010. J Pediatr 2012, 161(6):1091-1096.
4. Centers for Disease Control Prevention 2010 provisional pertussis surveillance report 2011, Available at www.cdc.gov [accessed 29.06].
5. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007, 7(9):614-624.
6. Centers for Disease Control Prevention (CDC) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60:1424-1426.
7. Centers for Disease Control and Prevention (CDC) National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Available at: [accessed 5.06.14]. http://www.cdc.gov/Features/Pertussis/.
8. Israel Ministry of Health Division of Epidemiology, letter number 51050612, date: 22 October 2012.
9. Israel Ministry of Health Division of Epidemiology, letter number 4112143, date: 18 July 2013.
10. Leurridan E., Hens N., Peeters N., de Witte L., Van der Meeren O., Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 2011, 30(7):608-610.
11. Gall S.A., Myers J., Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011, 204(4):334.e1-334.e5.
12. Hardy-Fairbanks A.J., Pan S.J., Decker M.D., et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J 2013, 32(11):1257-1260.
13. Healy C.M., Rench M.A., Baker C.J. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013, 56(4):539-544.
14. Munoz F.M., Bond N.H., Maccato M., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014, 311(17):1760-1769.
15. Baughman A.L., Bisgard K.M., Edwards K.M., et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004, 1045-1053.
16. Guiso N., Berbers G., Fry N.K. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011, 30(3):307-312.
17. Van Savage J., Decker M.D., Edwards K.M., Sell S.H., Karzon D.T. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990, 161(3):487-492.
18. Centers for Disease Control Prevention Pertussis (whooping cough), surveillance and reporting 2014, Available at: http://www.cdc.gov/pertussis/surv-reporting.html [accessed 5.06].
19. Levy O., Wynn J.L. A prime time for trained immunity: innate immune memory in newborns and infants. Neonatology 2014, 105:136-141.
20. Strunk T., Currie A., Richmond P., Simmer K., Burgner D. Innate immunity in human newborn infants: prematurity means more than immaturity. J Matern Fetal Neonatal Med 2011, 24(1):25-31.
21. Belderbos M.E., van Bleek G.M., Levy O., et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol 2009, 133(2):228-237.
22. de Greeff S.C., Mooi F.R., Westerhof A., et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010, 50(10):1339-1345.
23. Englund J.A. The influence of maternal immunization on infant immune responses. J Comp Pathol 2007, 137(Suppl. 1):S16-S19.
24. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of anti-pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003, 21:3542-3549.
25. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16(20):1901-1906.
26. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(20):1907-1916.
27. Taranger J., Trollfors B., Lagergård T., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection. J Infect Dis 2000, 181(3):1010-1013.
28. Heininger U., Riffelmann M., Bär G., Rudin C., von König C.H. The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J 2013, 32(6):695-698.
29. Jones C., Pollock L., Barnett S.M., Battersby A., Kampmann B. The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. Vaccine 2014, 32(8):996-1002.
30. Lewis J., Veal P., Shilliday L., Sloan M., Smithson R., Smyth B. Pertussis cases in neonates in Northern Ireland in 2013 following introduction of maternal vaccination in pregnancy. Presented at the 21st annual meeting of the European Society for Infectious Diseases 2014.
31. Halperin B.A., Morris A., Mackinnon-Cameron D. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011, 53(9):885-892.
32. Malek A., Sager R., Schneider H. Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy. Am J Reprod Immunol 1994, 32(1):8-14.
33. Brambell F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966, 2(7473):1087-1093.
34. Gusdon J.P. Fetal and maternal immunoglobulin levels during pregnancy. Am J Obstet Gynecol 1969, 103(7):895-900.
35. De Guow D., Diavatopoulos D.A., Bootsma H.J., Hermans P.W., Mooi F.R. Pertussis: a matter of immune modulation. FEMS Microbiol Rev 2011, 35(3):441-474.
36. Carbonetti N.H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010, 5(3):455-469.
37. Munoz J.J., Arai H., Bergman R.K., Sadowski P.L. Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun 1981, 33(3):820-826.
38. Morse S.I., Morse J.H. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of Bordetella pertussis. J Exp Med 1976, 143:1483-1502.
39. Melvin J.A., Scheller E.V., Miller J.F., Cotter P.A. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014, 12(4):274-288.
40. Hewlett E.L., Burns D.L., Cotter P.A., et al. Pertussis pathogenesis - what we know and what we don't know. J Infect Dis 2014, 209(7):982-985.
41. Mikelova L.K., Halperin S.A., Scheifele D., et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003, 143:576-581.
42. Paddock C.D., Sanden G.N., Cherry J.D., et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008, 47(3):328-338.